Drug development
The development of biotechnologically produced drugs has made it possible to treat diseases at their cause, to do this more efficiently and with fewer side effects, or even to cure diseases. This is the focus of five biotechnology companies on Campus Berlin-Buch.
The spectrum of their drug development includes highly specific cancer antibodies (Glycotope GmbH), novel treatments targeting the cause of heart failure (Berlin Cures GmbH) or atrial fibrillation (OMEICOS Therapeutics GmbH), extremely effective antibiotics (MerLion Pharmaceuticals) and RNAi-based therapeutics for systemic cancers that can selectively regulate disease-related genes (Silence Therapeutics).
News innovation
Eckert & Ziegler Records Solid Half-Year Results
Growth Trend for Radiopharmaceuticals Remains Intact
more ...T-knife Completes € 66 Million Series A Financing to Develop Next-Generation T-Cell Therapies
T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties
more ...Christopher Baum chosen to head the BIH
Events Campus
28.10.2020, 09:00
DIGITALE LIFE SCIENCES – Workshops zu den Grundlagen der Bioinformatik und zum Labor 4.0
Neuer Kurs für Technische Angestellten und Laboranten in den Life Sciences: Überblick über aktuelle Themen zur Bioinformatik, Digitalisierung und Automatisierung
more ...06.11.2020, 09:00
WEITERBILDUNGSTAG LABOR 4.0 FÜR TECHNISCHE ANGESTELLTE UND LABORANT*INNEN
09.11.2020, 09:00
Fachkraft für Molekularbiologie (TÜV)
Das 11-tägige Seminar vermittelt Grundlagen der wichtigsten Labormethoden der modernen Molekularbiologie und Einblicke in die klinische Forschung
more ...
